What type of study is this?

This is a In Vitro Study study.

What question did this study set out to answer?

This research evaluates aztreonam-avibactam's effectiveness against KPC-positive and ceftazidime-avibactam-resistant Enterobacterales.

January 14, 2026Open Access

P-1336. The in vitro activity of aztreonam-avibactam against KPC-positive and/or ceftazidime-avibactam-resistant Enterobacterales, ATLAS 2019-2023

Key Points

This research evaluates aztreonam-avibactam's effectiveness against KPC-positive and ceftazidime-avibactam-resistant Enterobacterales.
Analyzed 88,189 isolates from 226 medical centers in 56 countries.
Tested susceptibility using broth microdilution method according to CLSI guidelines.
Screened isolates for β-lactamase genes using PCR.
99.6% susceptibility of all tested isolates to aztreonam-avibactam with an MIC90 of 0.25 µg/mL.
99.8% susceptibility in KPC-positive isolates with an MIC90 of 0.5 µg/mL.
95.3% susceptibility in ceftazidime-avibactam-resistant isolates with an MIC90 of 2 µg/mL.

Abstract

Abstract Background Aztreonam-avibactam (ATM-AVI) is a β-lactam/β-lactamase inhibitor combination to treat infections caused by Gram-negative organisms, particularly those carrying metallo-β-lactamases (MBLs) and other β-lactamases. Aztreonam is stable to hydrolysis by MBLs and avibactam inhibits Class A, C, and some Class D enzymes. We examined ATM-AVI activity against Enterobacterales isolates that were either positive for the Class A carbapenemase KPC or resistant to ceftazidime-avibactam among isolates collected as a part of the ATLAS global surveillance program (2019-2023). Methods 88,189 isolates from 226 medical centers in 56 countries (excluding mainland China, Canada, and the USA) were collected and tested for susceptibility using the broth microdilution method according to CLSI guidelines. Analysis was performed with CLSI 2025 breakpoints. Isolates testing with meropenem MIC values 1 µg/mL or Escherichia coli, Klebsiella pneumoniae, K. oxytoca, or Proteus mirabilis isolates testing with ceftazidime and/or aztreonam MIC values 2 µg/mL were screened for β-lactamase genes by PCR. Results Of the 88,189 isolates characterized, 2039 screened positive for KPC and 3837 were resistant to ceftazidime-avibactam. Against these, ATM-AVI in vitro activity was (genotype/phenotype, percent susceptible, MIC90): All, 99.6%, 0.25 µg/mL; KPC-positive, 99.8%, 0.5 µg/mL; ceftazidime-avibactam-resistant 95.3%, 2 µg/mL (Table 1). No comparator agents were active against this many isolates in any group. Of isolates carrying KPC, ≥98% were susceptible to ATM-AVI, while CAZ-AVI activity was 91% (KPC-2), 94% (KPC-3), and 42% (other KPC), noting that some of these isolates co-carried MBLs (Figure 1). Conclusion Aztreonam-avibactam demonstrated potent in vitro activity against isolates that carry KPC carbapenemases and those that are ceftazidime-avibactam-resistant. While some uncommon variants of KPC can confer resistance to ceftazidime-avibactam, aztreonam-avibactam retained potency against these in vitro. Disclosures Katherine Perez, PhD, Pfizer: Stocks/Bonds (Public Company)

Read Full Paperexternally

Perguntar à IA

Bookmark

View Full Paper